225 related articles for article (PubMed ID: 2363853)
1. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
[TBL] [Abstract][Full Text] [Related]
3. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Stoudemire J; Mischak R; Spitler LE; Lopez H; Scannon P
Cancer Res; 1987 Mar; 47(5):1377-82. PubMed ID: 3493064
[TBL] [Abstract][Full Text] [Related]
5. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
[TBL] [Abstract][Full Text] [Related]
8. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
Spitler LE; Mischak R; Scannon P
Int J Rad Appl Instrum B; 1989; 16(6):625-7. PubMed ID: 2606718
[No Abstract] [Full Text] [Related]
9. The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.
Stoudemire JB; Mischak R; Foxall C; Harkonen WS; Del Rio M; Spitler LE
Mol Biother; 1990 Sep; 2(3):179-84. PubMed ID: 2222902
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody immunoconjugates in the diagnosis and treatment of advanced melanoma.
Bhardwaj S
Mt Sinai J Med; 1992 May; 59(3):207-10. PubMed ID: 1603109
[TBL] [Abstract][Full Text] [Related]
11. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
[TBL] [Abstract][Full Text] [Related]
12. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
[TBL] [Abstract][Full Text] [Related]
13. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
[TBL] [Abstract][Full Text] [Related]
15. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
16. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.
Hertler AA; Spitler LE; Frankel AE
Cancer Drug Deliv; 1987; 4(4):245-53. PubMed ID: 3502618
[TBL] [Abstract][Full Text] [Related]
18. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Byers VS; Baldwin RW
Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
[TBL] [Abstract][Full Text] [Related]
19. Phase I immunotoxin trial in patients with B-cell lymphoma.
Vitetta ES; Stone M; Amlot P; Fay J; May R; Till M; Newman J; Clark P; Collins R; Cunningham D
Cancer Res; 1991 Aug; 51(15):4052-8. PubMed ID: 1855219
[TBL] [Abstract][Full Text] [Related]
20. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.
Till M; May RD; Uhr JW; Thorpe PE; Vitetta ES
Cancer Res; 1988 Mar; 48(5):1119-23. PubMed ID: 3257712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]